# Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)

> **NCT04715932** · PHASE2 · COMPLETED · sponsor: **Montreal Heart Institute** · enrollment: 216 (actual)

## Conditions studied

- Covid19
- Anosmia
- Fever
- Cough
- Shortness of Breath
- Sore Throat
- Nausea
- Vomiting
- Headache
- Muscle Weakness
- Pain, Muscle
- Pain, Chest
- Pain, Joint
- Pain, Abdominal
- Pain
- Irritable Mood
- Confusion

## Interventions

- **DRUG:** Hesperidin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04715932
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-06-07
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2022-04-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04715932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04715932, "Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04715932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*